PCM
VERA icon

Prelude Capital Management’s Vera Therapeutics VERA Stock Holding History

Prelude Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,926
Closed -$1.2M – 1548
2026
Q1 		$1.2M Sell
29,926
-145
-0.5% -$6.25K 0.09% 261
2025
Q4 		$1.52M Sell
30,071
-16,480
-35% -$585K 0.11% 197
2025
Q3 		$1.35M Buy
46,551
+20,951
+82% +$485K 0.11% 241
2025
Q2 		$603K Buy
+25,600
New +$576K 0.06% 386

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Prelude Capital Management's VERA Position: Q2 2026 in Review

Prelude Capital Management sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 29,926 shares — an estimated $1.2M sold.

Prelude Capital Management first reported a position in VERA in Q2 2025 and held it in 4 quarters. The position peaked at $1.52M in Q4 2025. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Prelude Capital Management reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 29,926 Vera Therapeutics shares in Q2 2026, an estimated $1.2M.
  • Prelude Capital Management first reported a position in Vera Therapeutics in Q2 2025 and held it in 4 quarters.
  • Prelude Capital Management's Vera Therapeutics position peaked at $1.52M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.